Is Exenatide the Next Big Thing in Parkinson's Disease?
A recent study by Aviles-Olmos and colleagues suggests that 12 months of treatment with the glucagon-like peptide-1 receptor agonist exenatide improves motor and cognitive symptoms in Parkinson's disease (PD), and that the effect persists as long as 12 months after termination of the treatment. Due...
Na minha lista:
| Principais autores: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publishing
2014-08-01
|
| 叢編: | Journal of Parkinson’s Disease |
| 在線閱讀: | https://doi.org/10.3233/JPD-149001 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|